Fennec Pharmaceuticals (FRX) Stock Statistics & Valuation Metrics

Fennec Pharmaceuticals has a market cap or net worth of C$530.96M. The enterprise value is C$216.47M.

Fennec Pharmaceuticals has 34,737,030 shares outstanding. The number of shares has decreased by -2.65% in one year.

Fennec Pharmaceuticals’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -10.65%.

The current PE Ratio of Fennec Pharmaceuticals is ―. Fennec Pharmaceuticals’s PEG ratio is -0.00995.

In the last 12 months, Fennec Pharmaceuticals had revenue of 44.64M and earned -9.74M in profits. Earnings per share was -0.36.

In the last 12 months, operating cash flow was -5.78M and capital expenditures 0.00, giving a free cash flow of -5.78M billion.

Fennec Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Fennec Pharmaceuticals upcoming earnings date is Aug 6, 2026, TBA (Confirmed).

Fennec Pharmaceuticals as a current ratio of 6.34, with Debt / Equity ratio of 0.00%

In the past 12 months, Fennec Pharmaceuticals has paid 106.00K in taxes.

Fennec Pharmaceuticals EV to EBITDA ratio is -24.60, with an EV/FCF ratio of -14.70.

Fennec Pharmaceuticals has C$40.18M in cash and marketable securities with C$0.00 in debt, giving a net cash position of C$40.18M billion.

Gross margin is 92.23%, with operating margin of -14.22%, and net profit margin of -21.82%.

The average price target for Fennec Pharmaceuticals is C$22.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy